Algernon Pharmaceuticals Inc. (AGNPF)
AGNPF Stock Price Chart
Explore Algernon Pharmaceuticals Inc. interactive price chart. Choose custom timeframes to analyze AGNPF price movements and trends.
AGNPF Company Profile
Discover essential business fundamentals and corporate details for Algernon Pharmaceuticals Inc. (AGNPF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
11 Mar 2016
Employees
—
CEO
Christopher J. Moreau
Description
Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of nonalcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19 in Canada and Australia. The company's lead candidate is NP-120, an N-methyl-d-aspartate (NMDA) receptor glutamate receptor antagonist, which targets NMDA-type subunit 2B (Glu2NB), as well as exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress. It is also developing AP-188, a psychedelic compound that is part of the tryptamine family for the treatment of ischemic stroke in humans. Algernon Pharmaceuticals Inc. has an agreement with Charles River Laboratories for preclinical studies of AP-188 for the company's stroke clinical research program. Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.
AGNPF Financial Timeline
Browse a chronological timeline of Algernon Pharmaceuticals Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 27 Apr 2026
Upcoming earnings on 27 Jan 2026
Earnings released on 30 Jul 2025
Earnings released on 29 Apr 2025
EPS came in at -$0.01 .
Earnings released on 29 Jan 2025
EPS came in at -$0.01 .
Earnings released on 23 Dec 2024
EPS came in at -$0.01 .
Earnings released on 29 Jul 2024
EPS came in at $0.05 .
Earnings released on 16 Apr 2024
EPS came in at -$0.04 .
Earnings released on 29 Dec 2023
EPS came in at -$0.12 surpassing the estimated -$0.14 by +12.16%.
Earnings released on 30 Nov 2023
EPS came in at -$0.02 .
Earnings released on 31 May 2023
EPS came in at -$0.08 surpassing the estimated -$0.10 by +23.40%.
Stock split effective on 28 Mar 2023
Shares were split 1193 : 1000 , changing the number of shares outstanding and the price per share accordingly.
Stock split effective on 3 Mar 2023
Shares were split 4 : 1 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 28 Feb 2023
EPS came in at -$0.10 falling short of the estimated -$0.07 by -32.91%.
Earnings released on 30 Jan 2023
EPS came in at -$0.20 falling short of the estimated -$0.16 by -25.00%.
Earnings released on 25 Nov 2022
EPS came in at $0.30 surpassing the estimated -$0.17 by +276.47%.
Earnings released on 29 Jul 2022
EPS came in at $0.12 surpassing the estimated -$0.23 by +152.17%.
Earnings released on 26 Apr 2022
EPS came in at -$0.22 .
Earnings released on 27 Jan 2022
EPS came in at -$0.14 .
Earnings released on 25 Nov 2021
EPS came in at -$0.08 surpassing the estimated -$0.75 by +89.33%.
Stock split effective on 24 Nov 2021
Shares were split 1 : 100 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 30 Jul 2021
EPS came in at -$0.25 surpassing the estimated -$0.50 by +50.00%.
Earnings released on 29 Apr 2021
EPS came in at -$0.50 surpassing the estimated -$0.75 by +33.33%.
Earnings released on 29 Jan 2021
EPS came in at -$2.00 surpassing the estimated -$3.00 by +33.33%.
Earnings released on 18 Dec 2020
EPS came in at -$2.00 surpassing the estimated -$4.00 by +50.00%.
AGNPF Stock Performance
Access detailed AGNPF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.